Skip to main
XAIR

XAIR Stock Forecast & Price Target

XAIR Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Beyond Air is a biopharmaceutical company that is poised for success with its innovative NO Generator and Delivery System, strategic commercial leadership, and encouraging clinical data in both pulmonary hypertension and cancer indications. With a strong sales and operating focus, the company is well-positioned to drive utilization and establish key partnerships domestically and internationally, making it a promising investment choice. Key metrics such as increasing commercial revenue and strong clinical trial results contribute to a positive outlook for Beyond Air's stock.

Bears say

Beyond Air is facing several significant risks, including financial and capital risks due to their heavy reliance on external funding, commercialization risks due to the competitive market for respiratory treatments, and clinical development risks as their treatments are still in the early stages of testing. Additionally, the company faces several third-party dependency risks, as their success is tied to partnerships and collaborations. There are also intellectual property risks, as securing patents and protecting their technology may be costly. Operational risks, such as manufacturing and distribution challenges, could also impact the company's performance. Finally, there are stockholder and employee risks, as a negative outlook may lead to decreased investor confidence and talent retention.

XAIR has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beyond Air Inc (XAIR) Forecast

Analysts have given XAIR a Strong Buy based on their latest research and market trends.

According to 1 analysts, XAIR has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beyond Air Inc (XAIR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.